Investigational Compound Induces Significant Drop in Mutant Huntingtin Protein, Ongoing Trial Data Show
Huntington’s patients who were treated with the compound WVE-120102 showed a statistically significant drop in mutant huntingtin protein (HTT) in their cerebrospinal fluid, according to a recent Phase 1b/2a clinical trial. The compound was also found to be safe and well-tolerated. These data support the testing of higher dosages…